# US 2023/0068547 A1 · Compositions and methods for compartment-specific cargo delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068547 A1
- Document ID: US20230068547A1
- Status: Published application
- Kind: A1
- Application number: 17/293,830
- Filed: 2019-11-14
- Published: 2023-03-02
- Earliest claimed: 2018-11-14
- Assignees: Flagship Pioneering Innovations V, Inc.
- Applicants: Flagship Pioneering Innovations V, Inc.
- Inventors: Geoffrey A. von Maltzahn; John Miles Milwid; Jacob Rosenblum Rubens; Michael Travis Mee; Neal Francis Gordon; Jagesh Vijaykumar Shah; Kyle Marvin Trudeau; Brigham Jay Hartley
- Web page: https://patentgrep.com/patent/US20230068547A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/5176: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123)}
- A61K 38/164: {from bacteria}
- A61K 38/45: Transferases (2)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/09: containing a nuclear localisation signal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Fusosome compositions and methods are described herein.

## Claims

### Claim 1

A fusosome comprising:
(a) a lipid bilayer comprising a plurality of lipids derived from a source cell;
(b) a lumen surrounded by the lipid bilayer;
(c) a fusogen that is exogenous or overexpressed relative to the source cell, wherein the fusogen is disposed in the lipid bilayer, and wherein the fusogen is other than VSV-G; and
(d) a nuclear payload agent for delivery to the nucleus of a target cell, wherein the nuclear payload agent comprises or encodes a protein having a nuclear localization signal (NLS).

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The fusosome of claim 1, wherein the nuclear protein payload agent comprises a nuclear localization signal set forth in any one of SEQ ID NOS: 128-507 and 605-626.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The fusosome of claim 1, wherein;
the nuclear payload agent comprises or encodes: a nuclease, a transcription factor, a recombinase, an epigenetic factor, a post-transcriptional RNA modification factor, a non-coding RNA or ribonucleic protein, or a structural protein;
the nuclear payload agent comprises or encodes one or more of a transcriptional activator, transcriptional repressor, epigenetic modifier, histone acetyltransferase, histone deacetylase, histone methyltransferase, DNA methyltransferase, a DNA nickase, a site-specific DNA editing enzyme, optionally a deaminase, DNA transposase, DNA integrase, an RNA editor, an RNA splicing factor, or a PIWI protein; or
the nuclear payload agent comprises or encodes an antibody molecule, e.g., a Fab, an scFv, an scFab, a sdAb, a duobody, a minibody, a nanobody, a diabody, a zybody, a camelid antibody, a BiTE, a quadroma, or a bsDb.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The fusosome of claim 1, wherein the nuclear protein payload agent comprises or encodes a fusion protein comprising an effector domain and a localization domain, wherein:
the localization domain comprises a TAL domain, a Zinc Finger domain, a Cas9 domain, or a meganuclease domain; and
the effector domain comprises a nuclease, recombinase, integrase, base editor (deaminase), transcription factor, or epigenetic modifier.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The fusosome of claim 1, wherein the nuclear payload agent comprises or encodes a gene editing nuclease protein or nucleic acid.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The fusosome of claim 1, wherein the nuclear payload agent comprises:
(a) synthetic transcription factor that is a fusion protein comprising (i) a DNA binding domain, and (ii) a transcriptional activator domain or transcriptional repressor domain; or
(b) a synthetic epigenetic modifier that is a fusion protein comprising (i) a DNA binding domain and (ii) an epigenetic modifier domain.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The fusosome of claim 1, wherein the nuclear protein payload agent is or comprises a protein selected from fibrillarin; KRI1 homolog; nucleolar protein 11; upstream binding transcription factor, EBNA1 binding protein 2; coilin; promyelocytic leukemia; chromatin target of PRMT1; TERF1 interacting nuclear factor 2; ABL proto-oncogene 1, non receptor tyrosine kinase; lamin B1; centromere protein B; HI histone family member 0; kinetochore scaffold 1; RB binding protein 7, chromatin remodeling factor, signal transducer and activator of transcription 3; forkhead box P3; hepatocyte nuclear factor 4 alpha; runt related transcription factor 1; lymphoid enhancer binding factor 1; forkhead box PI; cut like homeobox 2; POU class 2 homeobox 1; SIX homeobox 3; RELA proto-oncogene, NF-kB subunit; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1; chromodomain helicase DNA binding protein 7: chromatin accessibility complex subunit 1; APOBEC1 complementation factor; bromodomain containing 4; Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1; lysine acetyltransferase 2A; histone acetyltransferase 1; TATA-box binding protein associated factor 5 like: lysine acetyltransferase 5; sirtuin 1; sirtuin 2; histone deacetylase 11; histone deacetylase 3; histone deacetylase 6; ASH1 like histone lysine methyltransferase; DOT1 like histone lysine methyltransferase; nuclear receptor binding SET domain protein 1; SET nuclear proto-oncogene; lysine methyltransferase 2A; lysine demethylase 2A; lysine demethylase 1A; lysine demethylase 3A; lysine demethylase 4B: lysine demethylase 5C: DNA methyltransferase 1; DNA methyltransferase 3 alpha; adenosine deaminase 2; adenosine deaminase, RNA specific; apolipoprotein B mRNA editing enzyme catalytic subunit 1; spliceosome associated factor 3, U4/U6 recycling protein; cyclin dependent kinase 19: cyclin LI; pre-mRNA processing factor 31; splicing factor 3a subunit 3; mediator of DNA damage checkpoint 1; ATM serine/threonine kinase; poly(ADP-ribose) polymerase 1; DNA topoisomerase I: or DNA ligase 4.

### Claim 20

A fusosome comprising:
(a) a lipid bilayer comprising a plurality of lipids derived from a source cell;
(b) a lumen surrounded by the lipid bilayer, wherein the lumen does not comprise an organelle;
(c) a fusogen that is exogenous or overexpressed relative to the source cell, e.g., wherein the fusogen is disposed in the lipid bilayer; and
(d) an organellar payload agent for delivery to a cytoplasmic organelle of a target cell, wherein, when a target cell is contacted with a plurality of the fusosomes, the organellar protein payload agent or polypeptide encoded therein becomes enriched in one or more of the Golgi apparatus, endoplasmic reticulum, vacuole, acrosome, autophagosome, centriole, glycosome, glyoxysome, hydrogenosome, melanosome, mitosome, cnidocyst, peroxisome, proteasome, vesicle, or stress granule of the target cell relative to the cyosol or plasma membrane of the target cell.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The fusosome of claim 20, wherein the organellar payload agent comprises or encodes a protein having a signal sequence which is not comprised by a naturally occurring counterpart of the protein.

### Claim 23

A fusosome comprising:
(a) a lipid bilayer comprising a plurality of lipids derived from a source cell;
(b) a lumen surrounded by the lipid bilayer;
(c) a fusogen that is exogenous or overexpressed relative to the source cell, wherein the fusogen is disposed in the lipid bilayer; and
(d) an organellar payload agent that comprises or encodes a heterologous signal sequence to the organellar payload agent that is sufficient to enrich the organellar payload agent in a cytoplasmic organelle of a target cell.

### Claim 24 (depends on 23)

The fusosome of claim 23, wherein the cytoplasmic organelle is chosen from a mitochondrion, Golgi apparatus, lysosome, endoplasmic reticulum, vacuole, endosome, acrosome, autophagosome, centriole, glycosome, glyoxysome, hydrogenosome, melanosome, mitosome, cnidocyst, peroxisome, proteasome, vesicle, or stress granule.

### Claim 25 (depends on 23)

The fusosome of claim 23, wherein:
the cytoplasmic organelle is a mitochondrion and the heterologous signal sequence is set forth in any one of SEQ ID NOS: 537-597;
the cytoplasmic organelle is a peroxisome, and the heterologous signal sequence is set forth in any one of SEQ ID NOS: 508-536;
the cytoplasmic organelle is a lysosome, and the heterologous signal sequence is set forth in any one of SEQ ID NOS: 39-71 and 605-608;
the cytoplasmic organelle is an endoplasmic reticulum, and the heterologous signal sequence is set forth in any one of SEQ ID NOS: 72-93, 121-127 and 609; or
the cytoplasmic organelle is a Golgi apparatus, and the heterologous signal sequence is set forth in any one of SEQ ID NOS: 94-107 and 610.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 23)

The fusosome of claim 23, wherein the cytoplasmic organelle is mitochondrion and, wherein when a population of target cells is contacted with a plurality of the fusosomes the organellar payload agent becomes enriched in mitochondria of the target cell at a level at least 10%, 20%, 50%, 100%, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, or 100-fold higher than the level of the organellar payload agent in the cytoplasm or the target cell plasma membrane.

### Claim 33

(canceled)

### Claim 34 (depends on 20)

The fusosome of claim 20, wherein the organellar payload agent comprises or encodes a polypeptide chosen from:
i) a metabolic protein;
ii) a protease;
iii) a chaperone;
iv) a protein transport protein;
v) a mitochondrial ribosome protein;
vi) a mitochondrial transcription protein; or
vii) a mitochondrial replication protein.

### Claim 35 (depends on 20)

The fusosome of claim 20, wherein the organellar payload agent comprises a protein selected from B cell receptor associated protein 31; calnexin; KDEL endoplasmic reticulum protein retention receptor 3 (“KDEL” disclosed as SEQ ID NO: 125); reticulon 4; Sec61 translocon alpha 1 subunit; Sarcoplasmic/endoplasmic reticulum calcium ATPase 1; Derlin-2; Stress-associated endoplasmic reticulum protein 2; Reticulocalbin-2; Atlastin-3; cytochrome c, somatic; translocase of inner mitochondrial membrane 44: translocase of outer mitochondrial membrane 40; voltage dependent anion channel 2; coenzyme Q8B; Acetyl-CoA acetyltransferase, mitochondrial; Citrate synthase, mitochondrial; Cytochrome c oxidase subunit 7A-related protein, mitochondrial; Fumarate hydratase, mitochondrial; NADPFFadrenodoxin oxidoreductase, mitochondrial; Induced myeloid leukemia cell differentiation protein Mcl-1; NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13; Transcription factor A, mitochondrial; fatty acyl-CoA reductase 1; acetyl-CoA acyltransferase 1; ATP binding cassette subfamily D member 3; hydroxysteroid 17-beta dehydrogenase 4; peroxisomal biogenesis factor 14; Non-specific lipid-transfer protein; Peroxisomal biogenesis factor 19; Enoyl-CoA delta isomerase 2; Acyl-CoA-binding domain-containing protein 5; golgin A1; golgi integral membrane protein 4; golgi associated PDZ and coiled-coil motif containing; trans-golgi network vesicle protein 23 homolog C; zinc finger DHHC-type containing 7; Coatomer subunit delta; BSD domain-containing protein 1; Platelet glycoprotein 4; Conserved oligomeric Golgi complex subunit 7; Coatomer subunit epsilon; Protein FAM3C; Alpha-(1,6)-fucosyltransferase; General vesicular transport factor pi 15; Transmembrane protein 165; Vacuolar protein sorting-associated protein 54; Protein YIPF3; Fas associated factor family member 2; lysophosphatidylcholine acyltransferase 2; NAD(P) dependent steroid dehydrogenase-like; perilipin 3; patatin like phospholipase domain containing 2; cadherin 4; catenin beta 1; epidermal growth factor receptor; ezrin; syntaxin 4; ATP-binding cassette sub-family G member 2; Caskin-2; Junction plakoglobin; Neural cell adhesion molecule 1; Pannexin-1; Solute carrier family 2, facilitated glucose transporter member 1: Stomatin-like protein 3; FUS RNA binding protein; TAR DNA binding protein; TATA-box binding protein associated factor 15; EWS RNA binding protein 1; DEAD-box helicase 4 (“DEAD” is disclosed as SEQ ID NO: 766); TAR DNA-binding protein 43; Heterogeneous nuclear ribonucleoprotein A1; Heterogeneous nuclear ribonucleoproteins A2/B1; Nucleolysin TIA-1 isoform p40; centrosomal protein 164; doublecortin domain containing 2; keratin 8; myosin heavy chain 10; actin bet; Coiled-coil domain-containing protein 14; Keratin, type I cytoskeletal 18; Pericentrin; Tubulin alpha-1 A chain; or Actin, alpha skeletal muscle.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 20)

The fusosome of claim 20, wherein, when a population of target cells is contacted with a plurality of the fusosomes, the organellar payload agent becomes enriched in the cytoplasmic organelle of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of cells in the population of target cells.

### Claim 39 (depends on 1)

The fusosome of claim 1, wherein the source cell is a primary cell, a cultured cell, an immortalized cell, or a cell line.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

The fusosome of claim 1, wherein the source cell is allogeneic.

### Claim 42 (depends on 1)

The fusosome of claim 1, wherein the source cell is autologous.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 1)

The fusosome of claim 1, wherein the fusosome is from a source cell having a modified genome that exhibits reduced immunogenicity.

### Claim 46 (depends on 1)

The fusosome of claim 1, wherein the fusosome:
(i) has a diameter that is less than about 0.01% or 1%, of that of the source cell;
(ii) is a mammalian fusogen or a viral fusogen; or
(iii) is active at a pH of 6-8.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49 (depends on 1)

The fusosome of claim 1, wherein the fusosome comprises a targeting domain which localizes the fusosome to a target cell.

### Claim 50 (depends on 49)

The fusosome of claim 49, wherein the targeting domain interacts with a target cell moiety on the target cell.

### Claim 51 (depends on 1)

The fusosome of claim 1, wherein the target cell is in an organism or is a primary cell isolated from an organism.

### Claim 52

(canceled)

### Claim 53 (depends on 1)

The fusosome of claim 1, wherein the target cell is selected from an endothelial cell, a fibroblast, a blood cell, a stem cell, an embryonic stem cell, a myoblast, a parenchymal cell, an alveolar cell, a neuron a precursor cell, a progenitor cell, or an immortalized cell.

### Claim 54 (depends on 1)

A pharmaceutical composition comprising the fusosome of claim 1.

### Claim 55 (depends on 1)

A method of manufacturing a fusosome composition, comprising:
i) providing a plurality of fusosomes according to claim 1; and ii) formulating the plurality of fusosomes, fusosome composition, or as a pharmaceutical composition suitable for administration to a subject.

### Claim 56 (depends on 1)

A method of administering a fusosome composition to a subject, comprising administering to the subject a fusosome composition comprising a plurality of fusosomes according to claim 1, thereby administering the fusosome composition to the subject.

### Claim 57 (depends on 1)

A method of delivering a payload agent to a subject, comprising administering to the subject a fusosome composition comprising a plurality of fusosomes according to claim 1, wherein the fusosome composition is administered in an amount and/or time such that the payload agent is delivered.

### Claim 58 (depends on 1)

A method of treating a disease or disorder in a patient comprising administering to the subject a plurality of fusosomes according to claim 1, wherein the fusosome composition is administered in an amount and/or time such that the disease or disorder is treated.

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61 (depends on 12)

The fusosome of claim 12, wherein the nuclease is a Cas9.

### Claim 62 (depends on 61)

The fusosome of claim 61, wherein the Cas9 is complexed with a guide RNA.

### Claim 63 (depends on 17)

The fusosome of claim 17, wherein the DNA binding domain is a TAL domain, ZF domain, or Cas9 domain.

### Claim 64 (depends on 34)

The fusosome of claim 34, wherein the organellar payload agent comprises or encodes Ornithine Transcarbamylase (OTC).

### Claim 65 (depends on 1)

The fusosome of claim 1, wherein when contacted with a target cell population, the fusosome delivers the payload agent via a non-endocytic pathway.

### Claim 66 (depends on 65)

The fusosome of claim 65, wherein the level of payload delivered via a non-endocytic pathway for a given fusosome composition is 0.1-0.95, 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 0.9-0.95, or at least at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater than a chloroquine treated reference cell.

### Claim 67 (depends on 20)

The fusosome of any of claim 20, wherein the fusosome is a viral fusogen and the viral fusogen is other than VSV-G.

### Claim 68 (depends on 1)

The fusosome of claim 1, wherein the fusogen is a viral fusogen and the viral fusogen comprises a Class I viral membrane fusion protein, a Class II viral membrane fusion protein, a Class III viral membrane fusion protein, or a viral membrane glycoprotein.

### Claim 69 (depends on 68)

The fusosome of claim 68, wherein the fusogen comprises a paramyxovirus fusogen.

### Claim 70 (depends on 69)

The fusosome of claim 69, wherein the paramyxovirus fusogen comprises a Nipah virus protein F, a measles virus F protein, a tupaia paramyxovirus F protein, a paramyxovirus F protein, a Hendra virus F protein, a Henipavirus F protein, a Morbilivirus F protein, a respirovirus F protein, a Sendai virus F protein, a rubulavirus F protein, or an avulavirus F protein.

### Claim 71 (depends on 49)

The fusosome of claim 49, wherein the fusogen comprises the targeting domain.
